Live Breaking News & Updates on Mineralys therapeutics inc

Stay informed with the latest breaking news from Mineralys therapeutics inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mineralys therapeutics inc and stay connected to the pulse of your community

Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.7%

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shares fell 3.7% on Thursday . The company traded as low as $11.19 and last traded at $11.55. 134,670 shares changed hands during mid-day trading, a decline of 14% from the average session volume of 156,938 shares. The stock had previously closed at $12.00. Analyst Upgrades and […]

California , United-states , Barclays-plc , Mineralys-therapeutics-inc , Samsara-biocapital-gp-llc , Charles-schwab-investment-management-inc , Nasdaq , Goldman-sachs-group , York-mellon-corp , Mineralys-therapeutics , Get-free-report

Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.7%

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shares fell 3.7% during trading on Thursday . The company traded as low as $11.19 and last traded at $11.55. 134,670 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 156,938 shares. The stock had previously closed at $12.00. Analysts […]

United-states , American , Mineralys-therapeutics-company-profile , Goldman-sachs-group , American-international-group-inc , Jpmorgan-chase-co , Hermes-inc , Nasdaq , Samsara-biocapital-gp-llc , Mineralys-therapeutics-inc , Mineralys-therapeutics

Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 3.7%

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) shares fell 3.7% during trading on Thursday . The company traded as low as $11.19 and last traded at $11.55. 134,670 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 156,938 shares. The stock had previously closed at $12.00. Analysts […]

United-states , American , Samsara-biocapital-gp-llc , Mineralys-therapeutics-inc , Mineralys-therapeutics-company-profile , American-international-group-inc , Jpmorgan-chase-co , Hermes-inc , Nasdaq , Goldman-sachs-group , Mineralys-therapeutics

Mineralys Therapeutics (NASDAQ:MLYS) Coverage Initiated at The Goldman Sachs Group

The Goldman Sachs Group started coverage on shares of Mineralys Therapeutics (NASDAQ:MLYS – Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $30.00 price target on the stock. Separately, Lifesci Capital restated an outperform rating on shares of Mineralys Therapeutics in a research report on […]

New-york , United-states , California , Goldman-sachs-group , York-state-common-retirement-fund , Samsara-biocapital-gp-llc , Citigroup-inc , Nasdaq , Mineralys-therapeutics-inc , Financial-services-group-inc , Mineralys-therapeutics

Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Up to $12.61

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report)’s share price gapped up before the market opened on Friday . The stock had previously closed at $12.61, but opened at $12.93. Mineralys Therapeutics shares last traded at $13.11, with a volume of 47,880 shares. Analyst Ratings Changes A number of research firms recently commented on MLYS. […]

New-york , United-states , California , China , Financial-services-group-inc , China-universal-asset-management-co , Nasdaq , Mineralys-therapeutics-inc , Goldman-sachs-group , Samsara-biocapital-gp-llc , York-state-common-retirement-fund

Mineralys Therapeutics (NASDAQ:MLYS) Receives Outperform Rating from Lifesci Capital

Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report)‘s stock had its “outperform” rating reissued by research analysts at Lifesci Capital in a research note issued on Tuesday, Zacks.com reports. Lifesci Capital also issued estimates for Mineralys Therapeutics’ FY2024 earnings at ($2.04) EPS. Mineralys Therapeutics Trading Down 0.5 % NASDAQ:MLYS opened at $12.78 on Tuesday. The stock […]

Samsara-biocapital-gp-llc , Vanguard-group-inc , Mineralys-therapeutics-company-profile , Nasdaq , Catalys-pacific , Mineralys-therapeutics-inc , Samsara-biocapital , Securities-exchange-commission , Mineralys-therapeutics , Get-free-report , Lifesci-capital

Mineralys Therapeutics (NASDAQ:MLYS) Rating Reiterated by Lifesci Capital

Mineralys Therapeutics (NASDAQ:MLYS) Rating Reiterated by Lifesci Capital
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Samsara-biocapital-gp-llc , Nasdaq , Mineralys-therapeutics-company-profile , Vanguard-group-inc , Catalys-pacific , Samsara-biocapital , Mineralys-therapeutics-inc , Mineralys-therapeutics , Get-free-report , Lifesci-capital , Mineralys-therapeutic

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript

Mineralys Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.61, expectations were $-0.85.

United-states , American , America , David-rodman , Jon-congleton , Adam-levy , Mary-kate , Michael-difiore , Minji-kim , Nasdaq , Greg-harrison-at-bank , American-hypertension-association-scientific-sessions

Samsara Biocapital Gp, Llc Acquires 555,555 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) major shareholder Samsara Biocapital Gp, Llc purchased 555,555 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was bought at an average cost of $13.50 per share, with a total value of $7,499,992.50. Following the purchase, the insider now owns 5,074,916 shares […]

United-states , American , Jpmorgan-chase-co , American-international-group-inc , Nasdaq , Mineralys-therapeutics-company-profile , Mineralys-therapeutics-inc , Samsara-biocapital-gp-llc , Hermes-inc , Mineralys-therapeutics , Get-free-report

Mineralys Stock: 2nd Half 2024 Hypertension Data Readout (NASDAQ:MLYS)

Mineralys Stock: 2nd Half 2024 Hypertension Data Readout (NASDAQ:MLYS)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Nasdaq , Mineralys-therapeutics-inc , Novartis , Astrazeneca , Boehringer-ingelheim , Rocky-mountain-spotted-fever , Chronic-kidney-disease , Aldosterone-synthase-inhibitor , Mineralys-therapeutics ,